TaiMed Biologics (4147) — Cash Flow-to-Debt Ratio
Latest as of December 2025:
0.03x
TaiMed Biologics (4147) has a Cash Flow-to-Debt Ratio of 0.03x as of December 2025, meaning its operating cash flow of NT$25.95 Million could theoretically repay 0% of its total liabilities (NT$953.05 Million) in one year. Explore 4147 long-term investments to assets to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
0.03x
Operating CF / Total Liabilities
Operating Cash Flow
NT$25.95 Million
TWD
Total Liabilities
NT$953.05 Million
TWD
Data as of
Dec 2025
Most recent filing
TaiMed Biologics Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for TaiMed Biologics across 11 annual periods. Also explore 4147 total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for TaiMed Biologics (2015–2025)
Year-by-year debt coverage analysis for TaiMed Biologics. For market capitalisation and broader financial context, see 4147 market cap.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.20x | NT$191.14 Million | NT$953.05 Million | ▲ +151.6% |
| 2024 | -0.39x | NT$-379.55 Million | NT$976.34 Million | ▼ -1916.3% |
| 2023 | -0.02x | NT$-25.60 Million | NT$1.33 Billion | ▲ +95.6% |
| 2022 | -0.44x | NT$-605.21 Million | NT$1.39 Billion | ▼ -244.9% |
| 2021 | -0.13x | NT$-211.28 Million | NT$1.67 Billion | ▼ -11.6% |
| 2020 | -0.11x | NT$-201.94 Million | NT$1.78 Billion | ▲ +80.2% |
| 2019 | -0.57x | NT$-655.31 Million | NT$1.14 Billion | ▲ +22.2% |
| 2018 | -0.74x | NT$-522.86 Million | NT$710.55 Million | ▲ +70.0% |
| 2017 | -2.45x | NT$-516.48 Million | NT$210.71 Million | ▼ -25.2% |
| 2016 | -1.96x | NT$-172.29 Million | NT$87.99 Million | ▲ +88.3% |
| 2015 | -16.76x | NT$-446.26 Million | NT$26.63 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.